ALG12-CDG is a flight route operated by Air Algerie, connecting Algiers, Algeria to Charles de Gaulle Airport in Paris, France.

The symptoms of ALG12-CDG vary from person to person, but can include: developmental delays, intellectual disability, seizures, vision and hearing loss, skeletal abnormalities, and heart defects. Other symptoms may include poor muscle tone, poor coordination, and difficulty with feeding.

ALG12-CDG is caused by mutations in the ALG12 gene. This gene provides instructions for making an enzyme called alginate lyase. Mutations in this gene lead to a deficiency of this enzyme, which disrupts the production of alginate, a carbohydrate found in the cell walls of certain bacteria. This disruption leads to the signs and symptoms of ALG12-CDG.

At this time, there is no known cure for ALG12-CDG. Treatment focuses on managing the symptoms and complications of the condition. This may include physical therapy, occupational therapy, speech therapy, dietary modifications, and medications to manage seizures, pain, and other symptoms. In some cases, surgery may be recommended to correct certain physical abnormalities.

The risk factors for ALG12-CDG include:

1. Family history of the disorder
2. Mutation in the ALG12 gene
3. Consanguinity (marriage between close relatives)
4. Advanced maternal age
5. Exposure to certain environmental toxins or medications during pregnancy.

At this time, there is no known cure or medications for ALG12-CDG. Treatment is focused on managing the symptoms of the condition, which can include physical therapy, occupational therapy, speech therapy, and dietary modifications.